Incyte Corporation (BVMF:I1NC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 124.45B +49.8% |
| Revenue (ttm) | 30.15B +26.9% |
| Net Income | 8.35B +85.1% |
| EPS | 40.67 +79.7% |
| Shares Out | n/a |
| PE Ratio | 14.90 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9 |
| Open | 306.30 |
| Previous Close | 296.97 |
| Day's Range | 306.30 - 307.20 |
| 52-Week Range | 222.86 - 310.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial numbers in USD Financial StatementsNews
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte price target raised to $137 from $121 at Mizuho
Mizuho raised the firm’s price target on Incyte (INCY) to $137 from $121 and keeps an Outperform rating on the shares.
Incyte price target raised to $155 from $131 at Leerink
Leerink analyst Andrew Berens raised the firm’s price target on Incyte (INCY) to $155 from $131 and keeps an Outperform rating on the shares.
Incyte price target raised to $120 from $110 at JPMorgan
JPMorgan raised the firm’s price target on Incyte (INCY) to $120 from $110 and keeps a Neutral rating on the shares.
Damora Therapeutics price target raised to $40 from $35 at Wedbush
Wedbush raised the firm’s price target on Damora Therapeutics (DMRA) to $40 from $35 and keeps an Outperform rating on the shares. Relevant to Damora Therapeutics, Incyte (INCY) updated its…
Incyte price target raised to $109 from $99 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Incyte (INCY) to $109 from $99 and keeps a Sector Perform rating on the shares after its Q2 earnings…
Incyte price target raised to $130 from $112 at BMO Capital
BMO Capital raised the firm’s price target on Incyte (INCY) to $130 from $112 and keeps a Market Perform rating on the shares. The company’s Commercial strength and increasingly de-risked…
Incyte price target raised to $150 from $136 at Guggenheim
Guggenheim raised the firm’s price target on Incyte (INCY) to $150 from $136 and keeps a Buy rating on the shares after updating the firm’s model to reflect Q2 results.
Incyte price target raised to $119 from $104 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Incyte (INCY) to $119 from $104 and keeps an Equal Weight rating on the shares. A “solid” Q2 underscored consistency in the…
Incyte says EC approves Opzelura cream for treatment of AD
Incyte (INCY) announced that the European Commission has approved Opzelura cream for the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineu...
Incyte price target raised to $140 from $136 at BofA
BofA raised the firm’s price target on Incyte (INCY) to $140 from $136 and keeps a Buy rating on the shares following a “strong” Q2 performance and FY26 guidance raise.
Incyte price target raised to $150 from $140 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Incyte (INCY) to $150 from $140 and keeps a Buy rating on the shares. The company reported a “solid beat and raise”…
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis.
Incyte price target raised to $139 from $134 at Barclays
Barclays raised the firm’s price target on Incyte (INCY) to $139 from $134 and keeps an Overweight rating on the shares post the Q2 report. The company’s commercial trends remain…
Incyte price target raised to $145 from $123 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Incyte (INCY) to $145 from $123 and keeps a Buy rating on the shares. The company reported Q2 results, highlighted…
Incyte price target raised to $120 from $107 at Oppenheimer
Oppenheimer raised the firm’s price target on Incyte (INCY) to $120 from $107 and keeps an Outperform rating on the shares. The company reported solid Q2 results, driven by broad…
Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline
Shares of Prelude Therapeutics (PRLD) after moving higher after Incyte (INCY) in its Q2 earnings release that after a review of available data, it has discontinued further development of INCB160058…
Incyte lifts annual revenue forecast after settlement with CMS
Drugmaker Incyte Corp reported on Tuesday higher second-quarter earnings and raised its annual revenue forecast after it settled a lawsuit with the U.S. government over Medicaid rebates tied to ecze...
Incyte Earnings Call Transcript: Q2 2026
Revenue grew 38% year-over-year to $1.67B, driven by strong demand and a one-time CMS benefit. Guidance for 2026 was raised across net sales and key franchises, with Opzelura and hematology/oncology segments showing robust growth. Multiple late-stage pipeline assets and regulatory milestones support a diversified growth outlook.
Incyte Earnings release: Q2 2026
Incyte released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Incyte Slides: Q2 2026
Incyte has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Incyte Quarterly report: Q2 2026
Incyte has published its Q2 2026 quarterly earnings report on July 28, 2026.
Incyte reports Q2 EPS $3.09, consensus $2.15
Reports Q2 revenue $1.67B, consensus $1.49B. “Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development,” said Bill Meury, Chief Executi...
Incyte raises FY26 revenue view to $5.13B-$5.26B from $4.77B-$4.94B
Consensus $5.75B. Reaffirms FY26 Jakafi net sales view of $3.22B-$3.27B; raises FY26 Opzelura net sales to $860M-$890M from $750M-$790M
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates.